Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 150 No. 4142 (2020)

Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein – an observational study

Cite this as:
Swiss Med Wkly. 2020;150:w20361



The principality of Liechtenstein had its first COVID-19 case at the beginning of March 2020. After exponential growth, the pandemic’s first wave was contained, with the last case being diagnosed 52 days after the initial occurrence.


To characterise the COVID-19 pandemic in Liechtenstein.


All patients diagnosed in Liechtenstein were followed up until recovery and again 6–8 weeks after symptom onset. They were contacted every 2 days to record their clinical status until the resolution of their symptoms. The diagnosis of COVID-19 was based on clinical symptoms and molecular testing. Household and close workplace contacts were included in the follow-up, which also comprised antibody testing. In addition, public health measures installed during the pandemic in Liechtenstein are summarised.


During the first wave, 5% of the population obtained a reverse transcriptase polymerase chain reaction test. A total of 95 patients (median age 39 years) were diagnosed with COVID-19 (82 who resided in Liechtenstein), resulting in an incidence in Liechtenstein of 0.211%. One patient, aged 94, died (mortality rate 1%). Only 62% of patients could retrospectively identify a potential source of infection. Testing the patients’ household and close workplace contacts (n = 170) with antibody tests revealed that 25% of those tested were additional COVID-19 cases, a quarter of whom were asymptomatic. Those households which adhered to strict isolation measures had a significantly lower rate of affected household members than those who didn’t follow such measures. The national public health measures never restricted free movement of residents. Masks were only mandatory in healthcare settings. The use of home working for the general workforce was promoted. Gatherings were prohibited. Schools, universities, certain public spaces (like sports facilities and playgrounds), childcare facilities, nonessential shops, restaurants and bars were closed. Social distancing, hygienic measures, solidarity and supporting individuals who were at risk were the main pillars of the public health campaigns.


The close collaboration of all relevant stakeholders allowed for the complete workup of all COVID-19 patients nationwide. A multitude of factors (e.g., young age of the patients, low-threshold access to testing, close monitoring of cases, high alertness and adherence to public health measures by the population) led to the early containment of the first wave of the pandemic, with a very low rate of serious outcomes. Antibody testing for SARS-CoV-2 revealed a substantial proportion of undiagnosed COVID-19 cases among close contacts of the patients.


  1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. doi:.
  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:.
  3. Gautier J-F, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity (Silver Spring). 2020;28(5):848. doi:.
  4. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–61. doi:.
  5. Der Bundesrat. Neue Hygiene- und Verhaltensregeln zum Schutz gegen das neue Coronavirus. [accessed 2020 Jun 30]. Available from:
  6. Lemaitre JC, Perez-Saez J, Azman AS, Rinaldo A, Fellay J. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. Swiss Med Wkly. 2020;150:w20295.
  7. Der Bundesrat. Coronavirus: Bundesrat verbietet Ansammlungen von mehr als fünf Personen. [accessed 2020 Jun 30]. Available from:
  8. Der Bundesrat. Verordnung 2 über Massnahmen zur Bekämpfung des Coronavirus. (COVID-19). [accessed 2020 Jun 30]. Available from:
  9. Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. 2020;368(6489):395–400. doi:.
  10. Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global - Travel and the 2019 novel coronavirus. Travel Med Infect Dis. 2020;33:101578. doi:.
  11. Wells CR, Sah P, Moghadas SM, Pandey A, Shoukat A, Wang Y, et al. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proc Natl Acad Sci USA. 2020;117(13):7504–9. doi:.
  12. Bundesamt für Gesundheit. Neuartiges Coronavirus (COVID-19) Verdachts-, Beprobungs- und Meldekriterien 26.2.2020. [accessed 2020 Jun 30]. Available from:
  13. Amt für Statistik Fürstentum Liechtenstein. Bevölkerungsstatistik vorläufige Ergebnisse 31. Dezember 2019. [accessed 2020 Jun 30] Available from:
  14. Amt für Statistik Fürstentum Liechtenstein. Beschäftigungsstatistik 2018. [accessed 2020 Jun 30] Available from:
  15. Schiess P. Der Zollvertrag und die Massnahmen zur Bekämpfung des Coronavirus. Wie Schweizer Recht via Zollanschlussvertrag und Epidemiengesetz in Liechtenstein Anwendung findet. Bendern (Arbeitspapiere Liechtenstein-Institut, 65). [accessed 2020 Jun 26]. Available from:
  16. Regierung des Fürstentum Liechtenstein. Medienmitteilung 16.3.2020: Regierung verschärft Massnahmen zur Verlangsamung der Ausbreitung des Corona-Virus. [accessed 2020 Jun 26]. Available from:
  17. Regierung des Fürstentum Liechtenstein. Medienmitteilung 17.3.2020: Generelles Veranstaltungsverbot und weitere Schliessungen. [accessed 2020 Jun 26]. Available from:
  18. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. doi:.
  19. Regierung des Fürstentum Liechtenstein. Medienmitteilung 26.2.2020: Liechtenstein ist auf Coronavirus vorbereitet. [accessed 2020 Jun 26]. Available from:
  20. Regierung des Fürstentum Liechtenstein. Medienmitteilung 30.03.2020: - Drive-Through Anlage in Betrieb genommen. Regierung Liechtenstein. [accessed 2020 Jun 26]. Available from:
  21. Regierung des Fürstentum Liechtenstein. Medienmitteilung 11.03.2020: Besuchsverbot in Pflegeheimen. [accessed 2020 Jun 26]. Available from:
  22. Regierung des Fürstentum Liechtenstein. Medienmitteilung 11.02.2020: Regierung setzt Stab „neues Coronavirus 2019‐nCoV“ ein. [accessed 2020 Jun 26]. Available from:
  23. Liechtensteinisches Vaterland. Liemobil reduziert Fahrplan-Angebot. [accessed 2020 March 18]. Available from:;art171,414347
  24. Bundesamt für Gesundheit. Neuartiges Coronavirus (COVID-19) Verdachts-, Beprobungs- und Meldekriterien 20.03.2020. [accessed 2020 Jun 26]. Available from:
  25. Amt für Gesundheit Fürstentum Liechtenstein. Anweisung zu Selbstisolation. [accessed 2020 June 26]. Available from:
  26. Regierung des Fürstentum Liechtenstein. Medienmitteilung 17.04.2020: Regierung orientiert über das weitere Vorgehen in Zusammenhang mit dem Coronavirus. [accessed 2020 Jun 26]. Available from:
  27. Regierung Liechtenstein. Medienmitteilung 27.04.2020 - erste Massnahmen Lockerung [Internet]. Regierung Liechtenstein. 2020. [cited 2020 Sep 6] Available from:
  28. Regierung Liechtenstein. Medienmitteilung 30.04.2020 - weitere Lockerung [Internet]. Regierung Liechtenstein. 2020. Available from:
  29. Regierung Liechtenstein. Medienmitteilung 29.05.2020 - Start in eine neue Normalität [Internet]. Regierung Liechtenstein. 2020. [cited 2020 Sep 6] Available from:
  30. Regierung Liechtenstein. Medienmitteilung 24.06.2020 - Weitgehende Rückkehr zur Normalität [Internet]. Regierung Liechtenstein. 2020 [cited 2020 Sep 6]. Available from:
  31. Regierung Liechtenstein. Medienmitteilung 29.06.2020 - Contact tracing [Internet]. Regierung Liechtenstein. 2020. [cited 2020 Sep 6] Available from:
  32. Liechtensteiner Vaterland. «Es ist noch zu früh für eine Entwarnung». [accessed 2020 April 15]. Available from:;art171,416324
  33. Baron RC, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, et al. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. Clin Chem Lab Med. 2020: Epub ahead of print. doi:.
  34. Eidgenössisches Bundesamt für Gesundheit. COVID-19 in der Schweiz, Anzahl Tests. [accessed 2020 September 3]. Available from:
  35. Robert Koch Institut. Erfassung der SARS-CoV-2-Testzahlen in Deutschland (Stand 19.8.2020). Epidemiologisches Bulletin. 2020;34:1–2.
  36. Österreichisches Bundesministerium Soziales, Gesundheit, Pflege und Konsumentenschutz. Coronavirus, Aktuelle Informationen. [accessed 2020 September 3]. Available from:
  37. Der Standard. Aktuelle Zahlen zum Coronavirus. [accessed 2020 September 3]. Available from:
  38. Bundesamt für Gesundheit (BAG). Coronavirus Krankheit 2019 (COVID-19) Situationsbericht zur epidemiologischen Lage in der Schweiz und im Fürstentum Liechtenstein.
  39. Regierung des Fürstentum Liechtenstein. MEDIENMITTEILUNG Nr 362. [accessed 2020 June 29]. Available from:
  40. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss Med Wkly. 2020;150:w20225. doi:.
  41. Bicher MR, Rippinger C, Urach C, Brunmeir D, Siebert U, Popper N. Agent-Based Simulation for Evaluation of Contact-Tracing Policies Against the Spread of SARS-CoV-2. medRxiv. 2020:2020.2005.2012.20098970.
  42. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, et al. The role of asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis. medRxiv 2020:2020.2004.2025.20079103.
  43. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al.; Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;NEJMoa2020283. doi:.
  44. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. doi:.
  45. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020;173(4):262–7. doi:.
  46. Hella J, Cercamondi CI, Mhimbira F, Sasamalo M, Stoffel N, Zwahlen M, et al. Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin. PLoS One. 2018;13(4):e0195985. doi:.
  47. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–9. doi:.

Most read articles by the same author(s)

1 2 3 > >>